MindWalk (NASDAQ:HYFT) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of MindWalk (NASDAQ:HYFT) from a hold rating to a sell rating in a report issued on Saturday.

HYFT has been the topic of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. HC Wainwright reissued a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Finally, JonesTrading began coverage on shares of MindWalk in a report on Thursday, April 16th. They issued a “buy” rating and a $5.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, MindWalk has a consensus rating of “Moderate Buy” and an average price target of $5.00.

MindWalk Price Performance

Shares of MindWalk stock opened at $1.44 on Friday. MindWalk has a 1 year low of $0.99 and a 1 year high of $3.25. The stock has a 50-day moving average price of $1.56. The company has a market cap of $67.26 million, a PE ratio of -6.55 and a beta of 0.83. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings data on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $3.03 million for the quarter. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%. On average, equities analysts expect that MindWalk will post -0.21 EPS for the current fiscal year.

Institutional Investors Weigh In On MindWalk

Several large investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in MindWalk in the 4th quarter worth about $51,000. Bridgeway Capital Management LLC purchased a new stake in shares of MindWalk during the 4th quarter valued at about $91,000. Bank of Montreal Can grew its stake in shares of MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after acquiring an additional 24,500 shares during the period. XTX Topco Ltd grew its stake in shares of MindWalk by 118.6% in the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after acquiring an additional 44,331 shares during the period. Finally, Jane Street Group LLC grew its stake in shares of MindWalk by 147.3% in the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after acquiring an additional 96,018 shares during the period. 6.70% of the stock is currently owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.